CA11

Carbonic anhydrase-related protein 11 · O75493 · CA11 on Sugi Atlas →

345 patent compounds predicted against CA11, 263 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL31492016	0.75	4/20
Acetazolamide (SCHEMBL23219)	1.00	1/20
Acetazolamide (SCHEMBL2557036)	1.00	1/20
Acetazolamide (SCHEMBL40812)	0.97	1/20
Acetazolamide (SCHEMBL1998362)	0.97	1/20
Acetazolamide (SCHEMBL2845106)	0.97	1/20
Acetazolamide (SCHEMBL11301585)	0.97	1/20
Acetazolamide (SCHEMBL15513954)	0.97	1/20
Acetazolamide (SCHEMBL28346552)	0.97	1/20
Acetazolamide (SCHEMBL30094028)	0.97	1/20
Acetazolamide (SCHEMBL9390276)	0.93	1/20
Acetazolamide (SCHEMBL20553201)	0.93	1/20
Acetazolamide (SCHEMBL2324424)	0.82	1/20
SCHEMBL9796337	0.82	1/20
Acetazolamide (SCHEMBL9748691)	0.76	1/20
Acetazolamide (SCHEMBL289665)	0.74	1/20
Acetazolamide (SCHEMBL2112580)	0.74	1/20
Acetazolamide (SCHEMBL15312887)	0.74	1/20
SCHEMBL30260537	0.72	1/20
SCHEMBL11840140	0.72	1/20

Clinical trials — most relevant to CA11 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Follow-Up Care With or Without CEA Assessments in Patients Who Have Undergone Surgery for Stage II or Stage III Colorectal Cancer	PHASE3	COMPLETED
Radiotherapy to Patients With CA19-9-elevated Advanced Pancreatic Cancer	PHASE3	RECRUITING
Gallium-68 PSMA-11 PET in Patients With Biochemical Recurrence	PHASE2/PHASE3	COMPLETED
mFOLFIRINOX Plus Radiotherapy to Patients With CA19-9-normal Advanced Pancreatic Cancer Refractory to Chemotherapy	PHASE2	RECRUITING
mFOLFIRINOX Plus Radiotherapy to Patients With CA19-9-normal Advanced Pancreatic Cancer	PHASE2	RECRUITING
A Phase II Study of Adjuvant Immunotherapy Targeting KRAS G12D, KRAS G12V, or TP53 R175H for Participants With Advanced Gastrointestinal Malignancies	PHASE2	WITHDRAWN
Nocardia Rubra Cell Wall Skeleton in Combination With Prior Second- or Third-line Regimens for the Treatment of Potentially Hazardous Colorectal Cancer SD Status	PHASE2	RECRUITING
A Controlled Study of the Effectiveness of Oregovomab (Antibody) Plus Chemotherapy in Advanced Ovarian Cancer	PHASE2	COMPLETED
Immunotherapy of Cervical Cancer With V3-Cervix	PHASE2	UNKNOWN
Irinotecan Liposomes +5-FU/LV Versus Capecitabine in Patients of Recurrence After Resection of Resectable BTC	PHASE2	NOT_YET_RECRUITING
Biweekly SOLAR, as First-line C/T in Pts With Gastric, Pancreatic and Biliary Cancers	PHASE1	COMPLETED
Serum Retinoic Acid Induced Protein 14 (RAI14) and Metastasis Associated Cancer Colon -1 (MACC-1) in Breast Cancer	nan	UNKNOWN
Implication of Long Non-coding RNA CCDC144NL-AS1/Micro RNA-143-3p Axis Expression Level as Novel Signature in Colorectal Cancer	nan	COMPLETED
The Andromeda Study.Predictive Value of Combined Criteria to Tailor Breast Cancer Screening.	nan	COMPLETED
Protein Expression as a Potential Diagnostic Biomarker of Cervical Dysplasia and/or Cancer	nan	COMPLETED
The Etiology and Progression of Brain Tumors	nan	COMPLETED
A Longitudinal Study to Analyse the Correlation Between CAI and Bilirubin	nan	UNKNOWN
Urine Cadmium Levels in Predicting Pancreatic Cancer Risk in Patients With Chronic Pancreatitis	nan	COMPLETED
A Prospective Multicenter Diagnostic Biomarker Study to Discriminate Borderline From Stage I Invasive Ovarian Cancer	nan	RECRUITING
Carbohydrate Antigen 19-9 in Colorectal Cancer	nan	UNKNOWN
Detection of Plasma Circulating Tumor DNA in Gastric Cancer	nan	UNKNOWN
Study of Cerebrospinal Fluid Samples in Diagnosing Carcinomatous Meningitis in Patients With Cancer or Meningeal Syndrome	nan	UNKNOWN
Post-operative Monitoring of Gastric Cancer	nan	RECRUITING
Mesothelin as a New Tumor Marker for Ovarian Cancer	nan	UNKNOWN
Assessment of CA 19-9 in Patients' With Thyroid Malignancies	nan	UNKNOWN
Detection of Biomarkers in Abnormal Cervical Cells in Women With Abnormal Pap Test Results	nan	COMPLETED
The Role of HE4 in the Follow-up of Advanced Ovarian, Fallopian Tube and Primary Peritoneal Cancer	nan	UNKNOWN
Tumor Markers for Efficacy of Dual-Target Therapy in HER2+ Breast Cancer	nan	COMPLETED
Determination of Copper and Other Trace Elements in Serum Samples From Patients With Biliary Tract Cancers	nan	RECRUITING
Analysis the Positive Rate of Tumor Markers Among Physical Examination Population	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a CA11 binder may also engage these)

Protein	Name	Similarity
Q95203	—	1.000	Q95203 →
Q5R665	—	1.000	Q5R665 →
O70354	—	1.000	O70354 →
Q866X7	—	1.000	Q866X7 →
Q866X6	—	1.000	Q866X6 →
Q9MZ30	—	0.983	Q9MZ30 →
Q8CI85	—	0.977	Q8CI85 →
Q5R4U0	—	0.973	Q5R4U0 →
A0JN41	—	0.972	A0JN41 →
CA12	Carbonic anhydrase 12	0.972	landscape →
Q99988	—	0.970	Q99988 →
Q95323	—	0.970	Q95323 →
Q865C0	—	0.970	Q865C0 →
P20863	—	0.969	P20863 →
Q04997	—	0.969	Q04997 →
Q9Z0J7	—	0.968	Q9Z0J7 →
P15101	—	0.968	P15101 →
Q9N085	—	0.968	Q9N085 →
CA4	Carbonic anhydrase 4	0.968	landscape →
Q9NS85	—	0.968	Q9NS85 →
Q9Z0J6	—	0.968	Q9Z0J6 →
Q99N23	—	0.967	Q99N23 →
P28651	—	0.967	P28651 →
Q3U435	—	0.966	Q3U435 →
Q18932	—	0.966	Q18932 →
Q07104	—	0.966	Q07104 →
P0C0K6	—	0.966	P0C0K6 →
Q9Z1W4	—	0.966	Q9Z1W4 →
Q01634	—	0.965	Q01634 →
Q10462	—	0.965	Q10462 →